Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced it will host a conference call for its Q2 2012 financial results on Wednesday, July 25, 2012. Q2 2012 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Bloom & Burton Healthcare Investor Conference,...

Product to be launched as Absorica™ Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S....

Product to be launched as Absorica™ Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S....

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced its financial and operational results for the three months ended March 31, 2012 ("Q1 2012"). Q1 2012 Summary Achieved...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced it will host a conference call for its Q1 2012 financial results and hold its Annual Meeting of Shareholders on Friday, May 4,...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced that its partner, Medical Futures Inc. ("Medical Futures"), has launched Durela™ (extended-release tramadol) in Canada. The...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2011. Fiscal 2011 Summary Completed...

- Financial results to be released February 22, 2012 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 15, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) will host a conference call...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it reached a sales milestone for Lipofen®, the Company's fenofibrate product. This one-time milestone, which is based on sales...